USD 120.64 billion
Report ID:
SQMIG35B2179 |
Region:
Global |
Published Date: February, 2024
Pages:
260
|Tables:
96
|Figures:
76
Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2019 and is poised to grow from USD 128.29 billion in 2023 to USD 209.2 billion by 2031, growing at a CAGR of 6.3% in the forecast period (2024-2031).
The pursuit of sedentary and busy lifestyle in the global population has led in the prevalence of chronic disorders and exposure to central nervous system disorders like schizophrenia and Alzheimer's. This indicates thaThe central nervous system treatment often involves a multidisciplinary approach which is inclusive of neurosurgeons, neurologists, and physical therapists. Collaboration among specialists ensures a comprehensive care and a holistic approach to the treatment. Ongoing research in the field of neuroscience and CNS disorders continue to contribute to the development of novel treatment options. This includes continuous advancements in medical surgical techniques, gene therapies, and neuroimaging techniques. t the healthcare sector is equipped to tackle lifestyle related diseases and prepares the market with options for patients with significant treatment opportunities.
Global treatment rates for illnesses related to the central nervous system (CNS) is predicted to rise on the account of diagnostic and therapeutic advances. Additionally, over the upcoming years, market growth is likely to be boosted due to the growing prevalence of central nervous system illnesses and the rising demand for efficient therapy choices.
According to WHO research more than 1 billion individuals worldwide are affected by central nervous system disorders including Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and stroke. All of the major pharmaceutical companies have invested and developed innovative medicines for the treatment of CNS illnesses as a result of the significant unmet medical demand.
An increase in treatment rates, particularly in low- and middle-income countries, has been brought on by the increasing approval of generic medications as a result of the patent expirations of important products like Copaxone and Invega. For instance, the FDA approved two new generic versions of Copaxone in 2019, which is projected to significantly intensify market competition for CNS treatments. The introduction of novel drugs into the market for treating the central nervous system is encouraged by regulatory standards and rigorous clinical trials. The effectiveness, dose, formulation, and side effects of these medications are all closely watched. For the treatment of individuals with malignant gliomas, the U.S. FDA has designated CNS Pharmaceuticals' berubicin as an orphan medication.
In the past ten years, there have been significant R&D activities in the CNS treatment sector, which have led to the launch of innovative drug delivery systems. The adoption of a novel therapy to treat illnesses of the central nervous system is anticipated to expand as a result of developments in drug delivery methods.
US Central Nervous System Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 120.64 billion
Largest Segment
Fastest Growth
immunomodulatory drugs
Growth Rate
6.3% CAGR
To get more reports on the above market click here to Buy The Report
The global central nervous system treatment market segmentation is based on disease type, drug class, drug type and region. Based on disease type the market is segmented into neurovascular diseases, CNS trauma, mental health, neurodegenerative diseases, CNS Cancer and other segments. Based on drug class, the market is segregated into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, analgesics and other segments. Based on drug type the market segmentation spans biologics and non-biologics. Based on region the global central nervous system treatment market segmentation spans North America, Europe, Asia-Pacific and Rest of the world.
Central Nervous System Treatment Market Analysis by Disease type
Due to the increasing prevalence of neurological disorders, including multiple sclerosis and Alzheimer's disease the neurodegenerative diseases dominated the market. Growing R&D expenditures with the goal of creating prospective therapeutic candidates for the treatment of multiple sclerosis, Alzheimer's, etc. are also a component in the market's quick growth.
As an illustration, Dyno Therapeutics and Roche announced a collaborative license agreement to use Dyno's CapsidMap platform to develop next-generation adeno-associated virus (AAV) vectors for gene therapies for CNS disorders and liver-directed therapies for both Roche and Spark Therapeutics, (a member of the Roche Group) product portfolio.
Central Nervous System Treatment Market Analysis by Drug Type
Non-biologics dominated the global market and the dominance is caused by the regulatory body imposing less regulations than it did for the approval of biologics. Additionally, Biogen's Tecfidera, which treats multiple sclerosis, has the largest revenues due to its widespread prescription in the non-biologics market worldwide. During the projection period, the rising prevalence of neurological illnesses, strong government support and favorable health reimbursement are additional major growth drivers for the non-biologics market. Additionally, elements including the availability of prospective pipeline candidates and the government assistance in creation and approval of biologic CNS medications are anticipated to promote the expansion of the biologics segment.
To get detailed analysis on other segments, Request For Free Sample Report
By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.
With the second leading position, Europe followed the United States. This can be attributed to the advantageous reimbursement practices and broad access to healthcare provided by the public healthcare systems like the National Health Service (NHS) of the United Kingdom. A spectacular CAGR is predicted for the Asia-Pacific countries due to a number of causes, including an ageing population, changing healthcare infrastructure, a higher engagement of countries that produce biosimilar and over-the-counter drugs, and an increase in neurological illnesses.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Central Nervous System Treatment Market Drivers
Increasing prevalence of mental diseases and pipeline researches is substantially driving the market growth.
Central Nervous System Treatment Market Restraints
High cost of drug development and the regulatory hurdles to restrain the growth
Request Free Customization of this report to help us to meet your business objectives.
Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses.
Central Nervous System Treatment Market Top Players Company Profiles
Central Nervous System Treatment Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to the global central nervous system market report analysis, the global market is poised to witness significant growth opportunities due to availability of treatment options, and a large patient pool. In addition, the market expansion strategies pursued by the key players represent growth factors and are likely to attract global attention.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 120.64 billion |
Market size value in 2031 | USD 209.2 billion |
Growth Rate | 6.3% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
Historical Year | 2019 |
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Central Nervous System Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Central Nervous System Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Central Nervous System Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Central Nervous System Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Central Nervous System Treatment Market size was valued at USD 120.64 billion in 2019 and is poised to grow from USD 128.29 billion in 2023 to USD 209.2 billion by 2031, growing at a CAGR of 6.3% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35B2179
sales@skyquestt.com
USA +1 351-333-4748